1. Inicio
  2. Publicaciones
  3. Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Kayser S
  • Kramer M
  • Grenet J
  • Metzeler KH
  • Sustkova Z
  • Luskin MR
  • Brunner AM
  • Elliott MA
  • Gil C
  • Marini SC
  • Rácil Z
  • Cetkovsky P
  • Novak J
  • Perl AE
  • Platzbecker U
  • Stolzel, Friedrich
  • Ho AD
  • Thiede C
  • Stone RM
  • Rollig, Christoph
  • Schlenk RF
  • Levis MJ

Grupos

Abstract

To evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia in an international, multicenter survey on 97 patients (52%, t(8;21)(q22;q22); 48% inv(16)(p13q22)/t(16;16)(p13;q22)). Median age was 53 (range, 19-81) years. Complete remission (CR) after anthracycline-based induction (n=86) and non-intensive therapy (n=11) was achieved in 97% and 36% of the patients. Median follow-up was 4.43 years (95%-CI, 3.35-7.39 years). Median survival after intensive and non-intensive treatment was not reached and 0.96 years, respectively. In intensively treated patients, inv(16) with trisomy 22 (n=11) was associated with a favorable 4-year relapse-free survival rate of 80% (95%-CI, 59-100%) as compared to 38% (95%-CI, 27-54%; P=0.02) in all other CBF-AML/FLT3- ITD positive patients (n=75). Overall, 24 patients underwent allogeneic hematopoietic cell transplantation (allo-HCT), 12 in first CR and 12 after relapse. Allo-HCT in first CR was not beneficial (P=0.60); however, allo-HCT seems to improve median survival in relapsed patients compared to chemotherapy (not reached versus 0.6 years; P=0.002). Excluding inv(16) with trisomy 22, our data indicate that the outcome of CBF-AML patients with FLT3-ITD seems to be inferior compared to published data on those without FLT3-ITD, suggesting that prognostically these patients should not be classified as favorable-risk. FLT3-inhibitors may improve outcome in those patients.

Datos de la publicación

ISSN/ISSNe:
0390-6078, 1592-8721

HAEMATOLOGICA  FERRATA STORTI FOUNDATION

Tipo:
Article
Páginas:
836-843
PubMed:
34348451
Factor de Impacto:
2,528 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 30

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • STEM-CELL TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; 1ST COMPLETE REMISSION; TANDEM DUPLICATION; MUTATIONS; GENE; CHEMOTHERAPY; INV(16); T(8/21); IMPACT

Campos de Estudio

Cita

Compartir